Skip to main content

ORACEA® 40 mg* Capsules provide sustained anti-inflammatory effect with low plasma variability1,2

*30 mg immediate release & 10 mg delayed release beads
†Sixteen healthy subject in the ORACEA Capsules arm measured at 7 days; mean weight 75kg

Antibiotic resistance induced as early as 7 days with Doxycycline (100 mg)2,3

*p values compared to placebo, by Mann-Whitney U test
 

Lead the way in limiting the risk of resistance

  • Every year in the United States 2 million people are infected with bacteria that are resistant to antibiotics4

  • Doxycycline accounts for nearly 1 out of 3 tetracycline prescriptions—the most commonly prescribed antibiotics5

  • Microbial resistance occurred in 7 days with doxycycline 100 mg/day3

  • Non-antibiotic dose ORACEA Capsules remained below the antimicrobial threshold6,7

  • There are no clinical studies to demonstrate additional anti-inflammatory effects of Doxycycline above 40 mg in rosacea patients